55P Potential benefits of extensive genomic analysis in patients with KRAS mutated solid tumors: Concurrent alterations and potential targets

I.C. Jacobsen, I. Spanggaard, M. Hoejgaard, L. Belcaid, C. Qvortrup,C.W. Yde,A.Y. Schmidt,F.C. Nielsen, G.L. Willemoe, M.S. Dam,U. Lassen,K.S. Rohrberg

Annals of Oncology（2022）

引用 0|浏览4

暂无评分

摘要

The KRAS gene is mutated in approximately 22% of all tumors. This study aimed to investigate the distribution and frequency of concurrent alterations in different cancers across KRAS subtypes and in different KRAS subtypes across cancers, and to identify potentially actionable targets and patients who received targeted treatment matched to their genomic profile (GP).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要